AUTHORS
Salome Ghvinephadze, Carl A Berggren2, Patrick R Hodgson3, Kathleen E McGrath, PhD4, Paul D Kingsley, PhD5, James Palis, MD6, Marlies Petra Rossmann, MD, PhD7
AFFILIATIONS
1 University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States
2 University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States
3 University of Rochester Medical Center, Rochester, United States
4 University of Rochester Medical Center, Rochester, United States
5 University of Rochester Medical Center, Rochester, United States
6 University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States
7 University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States, University of Rochester Medical Center, Rochester, United States
ABSTRACT
The human bone marrow produces 2-3 million red blood cells per second in a process called erythropoiesis. Excessive death of erythroid precursors causes ineffective erythropoiesis and thus anemia. Regulatory mechanisms underlying erythroid cell death remain largely unknown. Our preliminary work suggests that protection of cells from ferroptosis, a type of programmed cell death characterized by iron-dependent lipid peroxidation, is essential for erythroid differentiation. Several factors have been shown to protect from ferroptosis, such as glutathione peroxidase 4 (GPX4), ferroptosis suppressor protein 1 (FSP1), and dihydroorotate dehydrogenase (DHODH), a central enzyme in de novo pyrimidine synthesis. We found that inhibition of DHODH by brequinar causes lipid peroxidation and anemia – exemplified by blocked embryonic globin expression and hemoglobin production – that can both be rescued by ferroptosis inhibitors such as liproxstatin-1. Notably, treating zebrafish embryos with a structurally unrelated DHODH inhibitor, BAY-2402234, also causes anemia, which, however, is not rescued by ferroptosis inhibitors. Our docking studies revealed that brequinar, besides binding DHODH, has a high predicted affinity for the ferroptosis suppressor FSP1, whereas BAY-2402234’s affinity for FSP1 is low. To determine whether FSP1 plays a role in erythropoiesis, we generated two fsp1 knockout zebrafish lines using a CRISPR/Cas9-mediated approach. We found that fsp1 mutant embryos do not display an erythroid defect on their own but only when combined with dhodh knockdown. Further, overexpression of either wild-type fsp1 or dhodh could partially rescue the anemia caused by brequinar. These results support a model in which, in vivo, DHODH and FSP1 act in concert to protect differentiating erythroid cells from ferroptosis. We investigated whether these interactions of ferroptosis-protective pathways are conserved between zebrafish and human erythropoiesis. Analysis of published transcriptomics datasets (An et al., Blood, 2014; Li et al., Blood, 2014) showed that, among the three anti-ferroptotic enzymes, GPX4 is the most highly and dynamically expressed during human erythroid differentiation. Consistent with this, pharmacologic inhibition of GPX4 or its CRISPR/Cas9-mediated knockout in CD34?-derived BEL-A cells induces lipid peroxidation that is rescued by liproxstatin-1. Additionally, while DHODH knockout combined with FSP1 inhibition did not induce lipid peroxidation, targeting DHODH in cells with low GPX4 levels synergistically increased lipid peroxidation. These findings indicate that, in human erythroblasts, DHODH acts in concert with GPX4 to suppress ferroptosis. To identify the downstream mechanisms by which liproxstatin-1 rescues erythropoiesis when de novo pyrimidine synthesis is blocked due to inhibited DHODH, we performed untargeted metabolomics analyses. Upon co-treatment with brequinar, liproxstatin-1 increased the levels of cytidine triphosphate and uridine triphosphate, indicating increased pyrimidine salvage pathway activity. These data suggest that liproxstatin-1, in addition to inhibiting lipid peroxidation, boosts the synthesis of pyrimidine salvage metabolites to rescue erythropoiesis. In summary, our studies show that erythroid differentiation requires suppression of ferroptosis, mediated by the coordinated activity of either DHODH and FSP1 or DHODH and GPX4. A comprehensive understanding of the factors that protect erythroid cells from lipid peroxidation and subsequent premature death will be key to identifying new therapeutic targets for diseases characterized by ineffective erythropoiesis.
DISCLOSURES
Salome Ghvinephadze: No relevant conflicts of interest to declare.